Home Forums Melanoma Diagnosis: Stage IV interesting report on zelboraf intermitent dosing

  • This topic is empty.
Viewing 5 posts - 1 through 5 (of 5 total)
  • Author
    Posts
  • #21861
    Violeta
    Participant

    http://onlinelibrary.wiley.com/doi/10.1111/bjd.12615/pdf

    Just wanted to share with you this recent report about an 85 years patient that is still surviving on intermittent treatment.

    my best wishes for all of you.

    #63778
    Catherine Poole
    Keymaster

    That is an interesting story. Our very own Dick had his 4 year anniversary on Zelboraf!

    #63779
    Violeta
    Participant

    Catherine Poole wrote:

    That is an interesting story. Our very own Dick had his 4 year anniversary on Zelboraf!


    :-) Indeed is amazing..

    Catherine, is Dick as well on intermittent dosing? .. I am very interested in details.

    Is intermittent dosing of Braf inhibitors subject of any clinical trial? Wondering why the discontinuous regime of this medicine is not more tested?

    Edit: I read this is more and more seen as an feasible way to overcome the tumor resistance in patients that already acquired it. Could be a big hope for those who progress on inhibitors..

    #63780
    Dick_K
    Participant

    I am not on intermittent dosing although I have had a few one week holidays over the past two years due to blood issues.

    #63781
    Violeta
    Participant

    Thanks a lot to let me know, Dick. Stay like this, it is extraordinary!

    However, I think patient situation in the above article is different than yours..He is not the same lucky. Reading carefully the article I am convinced that if he was going continuously on zelboraf he would get resistance. He simply delayed , because of discontinuation. I am not of course, a specialist, but who knows, maybe is a way to go in case of no choice.

    Well… like all of us, always thinking further. :)

    wish you all the best!

Viewing 5 posts - 1 through 5 (of 5 total)
  • The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.